Sugi Predict

Sugi Predict / Compounds / Di(Hydroxyethyl)Ether

Di(Hydroxyethyl)Ether

Di(Hydroxyethyl)Ether

SCHEMBL1686010

OCCCCO.OCCOCCO

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.77
▸ MAPK1 P28482 1/20 0.77
▸ MEN1 O00255 4/20 0.71
▸ KMT2A Q03164 4/20 0.71
▸ ALDH1A1 P00352 3/20 0.50
▸ THRB P10828 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ GAA P10253 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ LMNA P02545 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ CYP4F2 P78329 1/20 0.34
▸ CYP4A11 Q02928 1/20 0.34
▸ GPR84 Q9NQS5 1/20 0.32
▸ FFAR1 O14842 1/20 0.32
▸ FFAR4 Q5NUL3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triethylene Glycol SCHEMBL10907018 0.96 MEN1 (0.79) TSHRMAPK1MEN1KMT2AALDH1A1
Di(Hydroxyethyl)Ether SCHEMBL28289546 0.96 TSHR (0.71) TSHRMAPK1MEN1KMT2AALDH1A1
Tetraethylene Glycol SCHEMBL2590115 0.96 MEN1 (0.79) TSHRMAPK1MEN1KMT2AALDH1A1
1,5-Pentanediol SCHEMBL11430206 0.96 TSHR (0.71) TSHRMAPK1MEN1KMT2AALDH1A1
Triethylene Glycol SCHEMBL29064120 0.96 MEN1 (0.79) TSHRMAPK1MEN1KMT2AALDH1A1
Di(Hydroxyethyl)Ether SCHEMBL4816588 0.96 TSHR (0.71) TSHRMAPK1MEN1KMT2AALDH1A1
Triethylene Glycol SCHEMBL3066155 0.96 MEN1 (0.79) TSHRMAPK1MEN1KMT2AALDH1A1
1,6-Hexanediol SCHEMBL270712 0.96 TSHR (0.71) TSHRMAPK1MEN1KMT2AALDH1A1
SCHEMBL237717 0.93 — —
Triethylene Glycol SCHEMBL9787032 0.93 MEN1 (0.73) TSHRMAPK1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024126548-A1 SOLUTION FOR POST ETCH RESIDUE REMOVAL (PERR) BASF SE (DE) 2024-06-20 — — WO claimed
EP-4346922-A2 PACKAGING SOLUTIONS Bausch + Lomb Ireland Limited (IE) 2024-04-10 — — EP claimed
CN-114096567-A Glycophospholipid polymer networks and uses thereof 鲍希与洛姆伯股份有限公司 2022-02-25 — — CN claimed
WO-2021053057-A1 GRAFTED POLYMER AND USE THEREOF BAUSCH HEALTH IRELAND LIMITED (IE) 2021-03-25 — — WO claimed
WO-2020222914-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF BAUSCH & LOMB INCORPORATED (US) 2020-11-05 — — WO claimed
US-20200239601-A1 CROSSLINKED POLYMERIC NETWORK AND USE THEREOF SANTARUS, INC. 2020-07-30 — — US claimed
US-6420441-B1 DISPERSING REMOVABLE CROSSLINKED POLYMER POROGENS IN A POLYSILOXANE, CURING, AND HEATING TO REMOVE POROGEN; LOW DIELECTRIC CONSTANT; HIGH POROSITY; INSULATION MATERIALS SHIPLEY COMPANY, L.L.C. 2002-07-16 — — US claimed
US-12012238-B2 Packaging solutions BAUSCH + LOMB IRELAND LIMITED (IE) 2024-06-18 — — US disclosed
EP-4346922-A2 PACKAGING SOLUTIONS Bausch + Lomb Ireland Limited (IE) 2024-04-10 — — EP disclosed
US-20230407077-A1 GRAFTED POLYMER AND USE THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2023-12-21 — — US disclosed
US-11845813-B2 Crosslinked polymeric network and use thereof BAUSCH & LOMB INCORPORATED (US) 2023-12-19 — — US disclosed
US-11795320-B2 Grafted polymer and use thereof BAUSCH + LOMB IRELAND LIMITED (IE) 2023-10-24 — — US disclosed
US-11732060-B2 Crosslinked polymeric network and use thereof BAUSCH & LOMB INCORPORATED (US) 2023-08-22 — — US disclosed
US-4830916-A POLYETHERURETHANE MOLDED FOAM SOUND INSULATION BRIDGESTONE CORPORATION (JP) 1989-05-16 — — US disclosed
EP-0272856-A2 Method of manufacturing molded products and laminated structure including the molded products manufactured according to the method Bridgestone Corporation (JP) 1988-06-29 — — EP disclosed
US-4663302-A Bicyclic amide acetal modified catalysts for polyurethane polymer formation ASHLAND OIL (US) 1987-05-05 — — US disclosed
EP-0003437-B1 PROCESS FOR THE MANUFACTURE OF RESIN-MODIFIED POLYUREA FOAMS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-07-14 — — EP disclosed
US-4332936-A AMINE CATALYZED SUCROSE COPOLYMERIZATION MOBAY CHEMICAL CORPORATION (US) 1982-06-01 — — US disclosed
EP-0003437-A1 Process for the manufacture of resin-modified polyurea foams IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1979-08-08 — — EP disclosed
US-4140606-A Process for preparing a polymerizable (meth) acrylate oligomer SHOWA DENKO K.K. (JP) 1979-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11732060-B2 Crosslinked polymeric network and use thereof ALG1, CSGALNACT1, CD44 TSHR 3500/4885MAPK1 4105/4885MEN1 4311/4885
US-11845813-B2 Crosslinked polymeric network and use thereof CD44, GLMN, ALG1 TSHR 2945/4885MAPK1 1487/4885MEN1 2917/4885
US-20200239601-A1 CROSSLINKED POLYMERIC NETWORK AND USE THEREOF ALG1, CSGALNACT1, CD44 TSHR 3500/4885MAPK1 4105/4885MEN1 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.